IP Library Granted Patent US 7,452,983
Granted Patent B2
US 7,452,983 · App. 10/537,767 · Granted Nov 18, 2008

Protein which binds to Akt2

Assignee: Astellas Pharma Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,452,983
App. No.
10/537,767
Granted
Nov 18, 2008
Kind
B2
Abstract

A novel polypeptide, a polynucleotide, an expression vector, a cell transfected with the expression vector, a method for screening an insulin resistance improving agent and a carbohydrate metabolism improving agent, and a method for producing a pharmaceutical composition are provided. The polypeptide is useful in screening an insulin resistance improving agent and a carbohydrate metabolism improving agent. When the polypeptide is overexpressed in a fat cell, the activity of Akt2 is reduced. Fat cells express the polypeptide. The polynucleotide encodes the polypeptide. The expression vector includes the polynucleotide. The screening method uses the polypeptide to screen for an insulin resistance improving agent and a carbohydrate metabolism improving agent. The production method uses the substance obtained by the screening method as the active ingredient of the pharmaceutical composition. The pharmaceutical composition is useful for insulin resistance improvement and carbohydrate metabolism improvement.

Claims (17)

1. An isolated polypeptide which comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 and which binds to Akt-homolog-2 (“Akt2”).

2. An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4.

3. An isolated polynucleotide encoding

(1) a polypeptide which comprises the amino acid sequence of SEQ ID NO:2 and which binds to Akt-2,

(2)a polypeptide which comprises the amino acid sequence of SEQ ID NO:4 and which binds to Akt-2,

(3) a polypeptide consisting of the amino acid sequence of SEQ ID NO:2, or

(4) a polypeptide consisting of the amino acid sequence of SEQ ID NO:4.

4. An expression vector comprising a polynucleotide encoding

(1) a polypeptide which comprises the amino acid sequence of SEQ ID NO:2 and which binds to Akt-2,

(2) a polypeptide which comprises the amino acid sequence of SEQ ID NO:4 and which binds to Akt-2,

(3) a polypeptide consisting of the amino acid sequence of SEQ ID NO:2, or

(4) a polypeptide consisting of the amino acid sequence of SEQ ID NO:4.

5. An isolated cell transformed with an expression vector comprising a polynucleotide encoding

(1) a polypeptide which comprises the amino acid sequence of SEQ ID NO:2 and which binds to Akt-2,

(2) a polypeptide which comprises the amino acid sequence of SEQ ID NO:4 and which binds to Akt-2,

(3) a polypeptide consisting of the amino acid sequence of SEQ ID NO:2, or

(4) a polypeptide consisting of the amino acid sequence of SEQ ID NO:4.

Assignments (3)
CORRECTION TO REEL/FRAME 017390/0475 Recorded Aug 25, 2006
From: ENDO, YUKI; ENDOH, HIDEKI; UEDA, YOSHITAKA; KATO, MIYUKI; INABE, KAZUNORI
To: ASTELLAS PHARMA INC.
Reel/Frame 018241/0452 →
MERGER Recorded Sep 22, 2005
From: YAMANOUCHI PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 016570/0324 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2005
From: ENDO, YUKI; ENDOH, HIDEKI; UEDA, YOSHITAKA; KATO, MIYUKI; INABE, KAZUNORI
To: ASTELLAS PHARMA INC.
Reel/Frame 017390/0475 →
Priority Claims (2)
JP 2002-354155 · Dec 5, 2002 · national
JP 2003-206952 · Aug 8, 2003 · national
Continuity (1)
Related Publication 20060211041A1 · Sep 21, 2006